Ground Truth Peptides
← All peptides

Melanotan I (afamelanotide)

Melanotan-1, MT-I, MT-1, CUV1647, Nle4-D-Phe7-α-MSH, Scenesse, EI-_05x (Epitan)

The Ground Truth Score

four plain questions, never one number

FDA-approved for a rare disease; thin evidence for the tanning use people actually want it for.

Bottom line

The genuine rare high-evidence peptide, two phase III RCTs and FDA approval for erythropoietic protoporphyria, but that grade does NOT transfer to the cosmetic tanning use, where evidence is only small open-label pilots and the product is a gray-market injectable.

Does the science back it?

AProven in humans

Do real people feel it?

Mixed

Is it safe?

BCharacterized

Could it be placebo?

Probably real

"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.

Why is the evidence this thin? It's mostly economics →

Dose at a glance

full dosing ↓

APPROVED (not a recommendation to self-use): one SCENESSE implant containing 16 mg afamelanotide, inserted subcutaneously above the anterior supra-iliac crest by a trained provider every 2 months.

Reported, not prescribed. Verify your vial and your math.

First documented human use

First controlled human use 1991 (Levine et al., JAMA. SC α-MSH analogue induced measurable tanning in volunteers); formal pharmacokinetic/dose-ranging human studies 1996 (Dorr/Levine, skin types III-IV). This is one of the few peptides where the question is genuinely settled: pivotal phase III RCTs were completed and the drug is FDA-approved (Oct 8, 2019, for EPP).

Photoprotection (EPP)Sunless tanning (off-label)Repigmentation (vitiligo, investigational)
The deep dive

The pitch

What people claim it does

Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.

  • Increases eumelanin (the photoprotective pigment) in skin without UV exposure by agonizing the MC1 receptor
  • Lets EPP patients tolerate far more pain-free light, restoring quality of life in a disease with no prior effective treatment
  • A 'natural-looking,' gradual tan with none of the sexual side effects of its cousin Melanotan II
  • Backed by real FDA approval and an EMA approval, not vaporware peptide marketing

The data behind each bullet

What actually backs it

A

FDA-approved (Oct 8, 2019) as the SCENESSE 16 mg subcutaneous implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).

FDA approval based on two randomized, double-blind, placebo-controlled phase III trials. EMA-approved since 2014. Orphan/rare-disease indication.

FDA Drugs@FDA. SCENESSE (afamelanotide) NDA 210797 ↗
A

In the U.S. phase III RCT, median pain-free direct-sunlight exposure was 69.4 h with afamelanotide vs 40.8 h placebo (P=0.04); the EU trial showed 6.0 h vs 0.8 h (P=0.005) over the study period.

Two multicenter double-blind placebo-controlled RCTs, n=168 total (86 drug / 81 placebo), published NEJM 2015;373:48-59. Quality-of-life and phototoxic-reaction secondary endpoints also favored drug.

PubMed. Langendonk et al., NEJM 2015, Afamelanotide for EPP ↗
C

Off-label/cosmetic tanning: it does produce melanin-independent tanning in healthy volunteers, but the human tanning evidence is only small open-label dose-ranging pilots (single-digit subject counts), not controlled efficacy or safety trials.

Original 1991-1999 open-label studies (Levine JAMA 1991; Dorr 1996 PK; dose-ranging n=8). No randomized controlled trial has ever tested or approved afamelanotide for cosmetic tanning; gray-market injectable MT-I is unregulated and often mislabeled vs Melanotan II.

PubMed. Dorr et al. 1996, Skin pigmentation & PK of melanotan-I in humans ↗
C

Investigational for vitiligo (with NB-UVB) and previously trialed for polymorphous light eruption; vitiligo phase III (CUV105) ongoing with results expected H2 2026.

Active and prior company-sponsored phase III programs; vitiligo data not yet final, PLE program did not yield approval. Promising but unproven for these uses.

ClinicalTrials.gov, afamelanotide vitiligo / PLE trials ↗
C

Sexual side effects (spontaneous erections, libido changes) belong to Melanotan II, not Melanotan I, a key confound, since gray-market vendors and forums routinely mix up or mislabel the two.

MT-II is the cyclic non-selective melanocortin agonist responsible for the famous self-injection erection anecdote and PT-141/bremelanotide lineage; MT-I (linear, MC1R-predominant) is not associated with sexual effects per clinical reports.

PubMed search, melanotan adverse effects review ↗

Mechanism

How it's assumed to work

Synthetic linear analogue of α-melanocyte-stimulating hormone (α-MSH); agonizes the melanocortin-1 receptor (MC1R) on melanocytes, driving eumelanin synthesis independently of UV, plus antioxidant, DNA-repair-enhancing, and anti-inflammatory effects. Substitutions (Nle4, D-Phe7) make it ~resistant to enzymatic degradation, giving a far longer half-life than native α-MSH. Mechanism is established (approved drug), not assumed.

Dosing & handling

What users and clinicians report

Reported, not prescribed

APPROVED (not a recommendation to self-use): one SCENESSE implant containing 16 mg afamelanotide, inserted subcutaneously above the anterior supra-iliac crest by a trained provider every 2 months. Gray-market off-label users report reconstituted SC injections in the ~0.5-1 mg/day range during a 'loading' phase then less frequent maintenance, but this is unverified, unregulated, and outside any controlled trial. Original human dose-ranging used ~0.16 mg/kg/day SC.

Doses are REPORTED, not prescribed. Only the 16 mg bimonthly implant is studied and approved, and only for EPP under medical supervision. Injectable 'Melanotan 1' from peptide vendors has no established dose, no purity guarantee, and is frequently mislabeled, never assume vial contents match the label. Confirm any product identity before use.

Timing & food

Approved implant is dosed every 2 months independent of food (it is not oral; afamelanotide has zero oral bioavailability). For the implant, timing is driven by the start of high-light-exposure seasons in EPP. Gray-market injectors often dose in the evening to sleep through nausea/flushing, but there is no food-timing rationale because it is parenteral and the effect is cumulative pigment build-up, not acute.

Half-life

Apparent half-life ~15 hours from the controlled-release SC implant; median Tmax ~36 h, mean Cmax ~3.7 ng/mL. Drug is generally undetectable in plasma within ~2-3 days of implant placement, while the pigmentation effect persists for weeks (hence the 2-month dosing interval). Native α-MSH, by contrast, degrades within minutes.

Reconstitution sensitivity

The approved product is a solid bioresorbable implant (no reconstitution). For gray-market lyophilized injectable powder, peptide-handling norms apply: reconstitute gently with bacteriostatic water, do not shake, refrigerate after mixing, protect from light and heat. Reconstitution quality is unverifiable for unregulated product, which is itself a core risk.

Real-world signal

What people actually report

Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.

Mixed signal· Reports exist but contradict each other.

Volume

Moderate-to-high chatter, but skewed: most online volume is about Melanotan II (the stronger tanning + libido peptide) and PT-141, with MT-I discussed comparatively less and frequently confused with MT-II. EPP-patient communities (e.g., porphyria foundations) discuss the approved drug seriously and separately from the tanning crowd.

Consistency

Mixed/inconsistent. EPP patient and clinical sources are consistent and positive about real benefit. The tanning-forum signal is muddier: users agree MT-I tans more slowly and 'cleaner' than MT-II (fewer side effects) but many find it underwhelming versus MT-II and pivot to the stronger compound, so the cosmetic signal partly self-selects toward its sibling.

Source credibility

Two-tier. High-credibility: peer-reviewed trials, FDA/EMA, and disease-foundation sources for the EPP indication. Low-credibility: most tanning-peptide vendor sites and 'peptide wiki' pages are affiliate/commercial, conflate MT-I and MT-II, and recite dosing with no controlled-trial basis, discount these heavily.

  • EPP patients and porphyria communities broadly report genuine, life-changing increases in tolerable sun/light exposure, among the most credible positive signals for any peptide, backed by the trials.
  • Cosmetic-tanning users say MT-I builds a slower, more natural-looking tan than Melanotan II and lacks the nausea/flush/erection effects, but many find it 'too mild' and switch to MT-II for faster results.
  • Recurring complaints across off-label users: new or darkening moles and freckles, uneven pigmentation, and nausea/flushing during loading, plus persistent confusion over whether vendor 'MT-1' is actually MT-2.
  • Skeptical/clinical voices repeatedly warn that the gray-market injectable is unregulated, frequently mislabeled, and that long-term melanoma risk is unknown, and that the FDA approval applies only to the EPP implant, not to buying it online to tan.

Placebo risk, Low

Placebo risk is LOW because the core endpoint is objective and measurable: increased skin melanin/pigmentation (visibly darker skin, measurable by reflectance) and, in EPP, photoprovocation tolerance and recorded pain-free light hours under double-blind RCT conditions. Skin doesn't darken by belief. (Subjective comfort/QoL components carry some placebo susceptibility, but the pigmentation readout anchors it.)

Risk panel

What could go wrong

Adverse events

In the regulated implant: implant-site reactions ~21% (mainly discoloration/pain/erythema/hematoma), nausea ~19%, headache ~20%, plus oropharyngeal pain, fatigue, dizziness, somnolence, and skin/mucosal hyperpigmentation. Generalized skin darkening and darkening/new melanocytic nevi occur, full-body skin exams are advised twice yearly. No drug-related serious adverse events in the pivotal trials.

Theoretical concerns

Because MC1R agonism darkens existing nevi and stimulates melanocytes, there is a theoretical (unquantified) concern about masking or promoting melanoma; long-term carcinogenicity data are limited and monitoring is mandated rather than reassured. Generalized hyperpigmentation is cosmetically irreversible until the drug clears.

Contraindications

Approved only for adults; hepatic/renal impairment not formally studied (caution). The label mandates periodic full-body dermatologic surveillance. Not indicated or studied in pregnancy/lactation. As an implant, requires trained in-office insertion.

Honest unknowns

The dominant real-world risk is NOT the approved drug, it is the gray-market injectable 'Melanotan 1' sold online and in gyms: unverified identity/purity, frequently conflated with or substituted by Melanotan II (which adds nausea, priapism, and cardiovascular effects), non-sterile reconstitution, and self-injection. Long-term melanoma risk of chronic off-label use is genuinely unknown.

Confound watch

Three big confounds: (1) MT-I vs MT-II conflation, sexual side effects, the worst safety case reports (priapism, rhabdomyolysis, AKI, renal infarction, melanoma case reports), and 'fat loss/libido' claims belong to non-selective MT-II, not MT-I; (2) the FDA halo, grade A is for EPP photoprotection, not for cosmetic tanning, where evidence is a handful of open-label volunteers; (3) tanning is self-reinforcing, users sun-expose more, which independently darkens skin, inflating perceived drug effect.

History

Discovery → first use → status

  1. Early 1980sSynthesized at University of Arizona (Hruby, Hadley, Levine) as a stable α-MSH analogue; hypothesis was a UV-free protective tan to reduce skin-cancer risk.
  2. 1991First controlled human demonstration of induced tanning via SC α-MSH analogue (Levine et al., JAMA).
  3. 1996Human pharmacokinetic / dose-ranging studies (Dorr, Levine) establish SC bioavailability and tanning at modest doses.
  4. 2005-2006Licensed to Australian biotech Epitan, which renamed to Clinuvel; compound designated CUV1647, then INN 'afamelanotide.'
  5. 2007-2011Phase II/III program in EPP (and PLE); pivotal EU trial Jan 2010-May 2011, U.S. trial May 2012-Jul 2013.
  6. 2014EMA approval as SCENESSE for EPP in the EU.
  7. Jul 2015Pivotal phase III RCT results published in NEJM.
  8. Oct 8, 2019FDA approves SCENESSE implant for EPP, first approved treatment for the disease.
  9. 2025-2026EMA expands to year-round dosing; vitiligo phase III (CUV105) readout expected H2 2026.

Verification

The COA standard, applied

Approval verified against FDA Drugs@FDA (NDA 210797, approved 2019-10-08) and DailyMed/EMA labeling; efficacy verified against the peer-reviewed NEJM 2015 phase III RCT (PMC4780255) with exact endpoints and p-values; tanning evidence verified against the original 1991/1996 human studies (PMID 9113347). Adverse-event percentages cross-checked between FDA review and EMA SmPC. MT-I vs MT-II distinction verified across DermNet and review literature.

The full verification standard →

Sources

Where this comes from

The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.

New posts, every couple weeks

Drop your email and I'll send new posts when they go up. No spam, nothing for sale, unsubscribe whenever.